Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis
OX40抑制剂telazorlimab治疗中重度特应性皮炎的IIb期随机试验
期刊:Journal of Allergy and Clinical Immunology Global
影响因子:
doi:10.1016/j.jacig.2023.100195
Rewerska, Barbara; Sher, Lawrence D; Alpizar, Sady; Pauser, Sylvia; Pulka, Grazyna; Mozaffarian, Neelufar; Salhi, Yacine; Martinet, Camille; Jabert, Wafaa; Gudi, Girish; Ca, Vinu; Gn, Sunitha; Macoin, Julie; Anstett, Victor; Turrini, Riccardo; Doucey, Marie-Agnès; Blein, Stanislas; Konto, Cyril; Machkova, Martina
